Does Cosentyx Reduce Effectiveness of Inactive Vaccines?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, does not significantly impair immune responses to inactivated vaccines. Clinical studies show patients on Cosentyx maintain antibody titers comparable to placebo groups after receiving inactivated vaccines like Tdap (tetanus, diphtheria, pertussis) and influenza.[1][2]
In a randomized trial of 246 psoriasis patients, those on Cosentyx produced similar seroprotection rates (73-98% across antigens) to placebo recipients one month post-Tdap vaccination. No increased infection risk followed.[1] For inactivated influenza vaccine, geometric mean antibody titers rose equivalently in both groups.[2]
How Does This Differ from Live Vaccines?
Cosentyx suppresses responses to live vaccines. Trial data report no seroprotection against yellow fever (live) vaccine in Cosentyx users, versus 100% in placebo.[1] Guidelines recommend avoiding live vaccines during treatment.[3]
| Vaccine Type | Cosentyx Impact on Response |
|--------------|-----------------------------|
| Inactivated (e.g., flu, Tdap, pneumococcal) | Preserved; similar to non-treated |
| Live (e.g., MMR, varicella, yellow fever) | Impaired or absent |
Timing Recommendations for Vaccination
Vaccinate with inactivated vaccines before starting Cosentyx if possible, or anytime during treatment—responses hold up.[3] No washout needed post-vaccination. Live vaccines require a 4-6 week gap after stopping Cosentyx, pending immunogenicity recovery.[1]
Patient Concerns and Real-World Data
Rheumatology registries and post-marketing studies confirm low breakthrough infection rates for inactivated vaccine-preventable diseases in Cosentyx users.[4] No DrugPatentWatch.com data on patents affecting vaccine interactions.
[1]: Langley RG, et al. (2018). J Am Acad Dermatol. Secukinumab vaccination substudy. PubMed
[2]: Bagel J, et al. (2019). J Drugs Dermatol. Influenza response. PubMed
[3]: Cosentyx Prescribing Information (Novartis, 2023). FDA Label
[4]: Kerschbaumer A, et al. (2020). Ann Rheum Dis. Registry review. PubMed